Fin Dec Wealth Services, Inc. Cardiff Oncology, Inc. Transaction History
Fin Dec Wealth Services, Inc.
- $158 Billion
- Q2 2024
A detailed history of Fin Dec Wealth Services, Inc. transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Fin Dec Wealth Services, Inc. holds 16,000 shares of CRDF stock, worth $41,600. This represents 0.02% of its overall portfolio holdings.
Number of Shares
16,000
Previous 16,000
-0.0%
Holding current value
$41,600
Previous $85.4 Million
58.43%
% of portfolio
0.02%
Previous 0.05%
Shares
1 transactions
Others Institutions Holding CRDF
# of Institutions
98Shares Held
12.8MCall Options Held
823KPut Options Held
78K-
Black Rock Inc. New York, NY2.63MShares$6.83 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.14MShares$5.55 Million0.0% of portfolio
-
Assenagon Asset Management S.A.1.22MShares$3.16 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA911KShares$2.37 Million0.0% of portfolio
-
State Street Corp Boston, MA805KShares$2.09 Million0.0% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $113M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...